文献速递小儿眼科与斜弱视

A型肉毒毒素注射治疗斜视:美国眼科学会报告

Botulinum Toxin Injection for the Treatment of Strabismus: A Report by the American Academy of Ophthalmology.
PubMed 文献 · Ophthalmology · 2021-06-25

该报告系统回顾了眼外肌A型肉毒毒素注射与眼肌手术治疗非麻痹性、非限制性水平斜视的疗效对比证据。纳入14项研究(2项随机临床试验、3项非随机比较研究、9项病例系列),比较研究均为II级证据,病例系列为III级证据。肉毒毒素注射的运动成功率为60%,手术为66%-77%,两者无显著差异,但一项II级研究中肉毒毒素注射成功率显著更高(94% vs 72%)。

要点

  • 肉毒毒素注射治疗水平斜视的运动成功率与手术相当,约为60%。
  • 儿童一次注射两条肌肉成功率可达87%-89%,成人单肌肉注射成功率较低。
  • 良好眼位可能需多次注射,幼儿感觉性结局是否等同手术尚不明确。

核心结论

  • 眼外肌A型肉毒毒素注射治疗非麻痹性、非限制性水平斜视的运动成功率较高,与眼肌手术相当。
  • 良好眼位可能需要多次注射,幼儿感觉性结局是否与手术等同尚不明确。

研究设计与样本

  • 美国眼科学会报告,检索PubMed、Cochrane图书馆和临床试验数据库至2021年1月10日,限英文文献。
  • 初检515篇,全文审阅40篇,最终纳入14篇:2项随机临床试验、3项非随机比较研究、9项病例系列。
  • 纳入标准:比较研究或样本量≥50的病例系列,评估眼外肌A型肉毒毒素注射用于初治或重复治疗水平非麻痹性非限制性斜视,随访至少6个月。
  • 5项比较研究均为II级证据,9项病例系列为III级证据。

主要发现

  • 5项比较研究中4项显示,校正选择偏倚后肉毒毒素注射运动成功率约为60%。
  • 上述4项研究中手术运动成功率为66%至77%,平均随访23至75个月,与肉毒毒素注射无显著差异。
  • 第5项II级研究中肉毒毒素注射成功率显著高于手术(94% vs 72%)。
  • III级病例系列中,儿童一次注射两条肌肉运动成功率为87%至89%;成人单肌肉注射成功率较低。

关键数值与推荐

  • 肉毒毒素注射运动成功率约60%,手术为66%至77%,两者无显著差异。
  • 一项II级研究中肉毒毒素注射成功率94%,手术72%,差异显著。
  • 儿童一次注射两条肌肉成功率87%至89%,成人单肌肉注射成功率较低。

临床怎么用

  • 对于非麻痹性、非限制性水平斜视,眼外肌A型肉毒毒素注射可作为眼肌手术的替代方案。
  • 临床应告知患者良好眼位可能需要多次注射。
  • 幼儿选择肉毒毒素注射时,需注意感觉性结局是否与手术等同尚不明确。

局限性

  • 纳入研究多为III级证据病例系列,高级别证据有限。
  • 幼儿感觉性结局是否与手术等同尚不明确。
  • 部分研究存在选择偏倚,需校正后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review the available evidence comparing the effectiveness of extraocular muscle botulinum toxin type A (BTXA) injection with eye muscle surgery for restoring ocular alignment in children and adults with nonparalytic, nonrestrictive horizontal strabismus. METHODS: Literature searches in the PubMed Cochrane Library, and clinical trial databases with no date restrictions, but limited to articles published in English, were conducted last on January 10, 2021. The searches yielded 515 citations, 40 of which were reviewed in full text by the first author. Fourteen articles met the criteria for inclusion (randomized or nonrandomized comparative studies, or case series with a minimum 50 patients; evaluating extraocular muscle BTXA injection for initial or repeat treatment of horizontal, nonparalytic, nonrestrictive strabismus; with at least 6 months of follow-up) and were graded by a methodologist. RESULTS: The 14 included studies consisted of 2 randomized clinical trials, 3 nonrandomized comparative studies, and 9 case series. All 5 comparative studies were graded level II evidence, and the 9 case series were graded level III evidence. Successful motor outcomes after BTXA injection were relatively consistent across 4 of the 5 comparative studies at 60%, when adjustment was made for differential selection bias in 1 of the studies. In the 4 studies, successful motor outcomes after surgery ranged from 66% to 77% with a mean follow-up of 23 to 75 months, and the outcomes were not significantly different from those after BTXA injection. In the fifth level II study, success was significantly higher with BTXA injection than with surgery (94% vs. 72%). The level III BTXA case series demonstrated higher motor success rates of 87% to 89% when children were treated in 2 muscles at a time; rates were lower in adults treated with single-muscle BTXA injection. CONCLUSIONS: Extraocular muscle injection of BTXA achieves a high rate of successful motor alignment, comparable with that achieved after eye muscle surgery for nonparalytic, nonrestrictive horizontal strabismus. Good alignment may require multiple BTXA injections, and it is not yet clear whether sensory outcomes are equivalent for BTXA injections versus eye muscle surgery in young children.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Binenbaum G, Chang MY, Heidary G, et al. Botulinum Toxin Injection for the Treatment of Strabismus: A Report by the American Academy of Ophthalmology. Ophthalmology. 2021. PMID: 34176652. doi:10.1016/j.ophtha.2021.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。